Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CBT102-A by CommBio Therapeutics for Phenylketonuria (PKU): Likelihood of Approval
CBT102-A is under clinical development by CommBio Therapeutics and currently in Phase I for Phenylketonuria (PKU). According to GlobalData, Phase...